Testosterone- muscling its way towards fighting diabetes – LLY, ABBV, BAYN & BDX

Boston, MA 02/25/2013 (wallstreetpr) – Gary Wittert, professor of medicine in Australia at the University of Adelaide set out on a search for baby boomers last month, to participate in a clinical trial. One day is all it took to get him 800 volunteers for the trial of free testosterone injections. The professor and his colleagues are of the opinion that the sex hormone that is widely used to increase musculature and libido may be helpful in the prevention of a certain form of late-life diabetes and over 330 million people across the world are afflicted by it. Winner of seven Tour De France titles, cyclist Lance Armstrong had admitted to using this steroid and apart from being a popular libido-boosting hormone, it could fight diabetes very effectively if the tests showed positive results.

Forever young and strong

Another important factor is that testosterone is inexpensive and very easy to make and the healthcare system will not have to bear any burden if it is launched. Eli Lilly & Co (NYSE:LLY) as well as AbbVie Inc (NYSE:ABBV) are a couple of companies that chemically replicate the hormone that is naturally produced in men’s testes. The demand for testosterone has been climbing across the world as well as in Australia. But sadly the target market is gullible men who buy the product as an anti-aging therapy. Bait advertising misleads them to believe that the hormone will boost their vigor and keep them youthful forever.

Increased testosterone deficiency

Nothing sells like sex does is what Professor of medicine Handelsman, from the Sydney University says. For various reasons, environmental and life-style related ones included, testosterone deficiency is on the rise and studies have shown that in America, close to 5 million men do not produce a sufficient amount of the hormone. What is heartening is that awareness is on the rise as well. The hormone is generally administered via gels, pills, injections, patches and gum tablets which are also known as torches. Testosterone diseases such as Klinefelters syndrome are treated by replacement therapy.

The flip side

It is important to understand that there are also a lot of side effects including aggression, sperm reduction, acne, impotence, baldness and breast enlargement. The National Health and Medical Research Council in Australia has committed $4.6 million towards a study that aims to establish whether the male hormone can effectively and safely complement a healthy diet to reduce the risk of diabetes in older men. Wittert and his colleagues will be recruiting 1,500 men between the age group of 50-74 years who are diabetic, for the study.

Caution and care

Either a placebo or the testosterone will be used in the study. Bayer AG (FRA: BAYN) will be the supplier of Nebido, the testosterone that will be used for the trial study and Dickinson and Co (NYSE:BDX) will be supporting it. Any trial of this scale has to be conducted with utmost caution as there are always chances of delayed reactions that stretch way beyond the tenure of the trial. A case in example was the routine hormone replacement therapy for menopausal women. After 30 years of use, it was found to lead to strokes and heart attacks. Proper research would need to be conducted to prevent history from repeating itself

Shares of Eli Lilly & Co (NYSE:LLY) were up by 15 and currently trading at $54.80

Shares of AbbVie Inc (NYSE:ABBV) were down by 0.83% and currently trading at $38.12

Shares of Bayer AG (FRA:BAYN) went up by 0.88% and currently trading at $73.76

Shares of Becton, Dickinson and Co (NYSE:BDX) were up by 0.43% and currently trading at $88.29

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.